Unique ID issued by UMIN | UMIN000016247 |
---|---|
Receipt number | R000018854 |
Scientific Title | Depressor and anti-inflammatory effects of angiotensin II receptor blockers in metabolic and/or hypertensive patients with coronary artery disease |
Date of disclosure of the study information | 2015/01/17 |
Last modified on | 2016/08/14 20:19:25 |
Depressor and anti-inflammatory effects of angiotensin II receptor blockers in metabolic and/or hypertensive patients with coronary artery disease
DIAMOND study
Depressor and anti-inflammatory effects of angiotensin II receptor blockers in metabolic and/or hypertensive patients with coronary artery disease
DIAMOND study
Japan |
Hypertension
Cardiology |
Others
NO
It is still controversial what types of angiotensin II type 1 receptor blockers (ARBs) are useful. We compare the efficacies (depressor effect and anti-inflammation) and safety of two kinds of ARBs (azilsartan vs. olmesartan) in patients with metabolic syndrome and/or hypertension who underwent coronary angiography. If the patients receive percutaneous coronary intervention, we assess depressor effect and in-stent restenosis at follow-up CAG.
Safety,Efficacy
Exploratory
Explanatory
Not applicable
Depressor effects and the percentage of patients who reach the target blood pressure.
1.Anti-inflammatory effects
2.Rate of in-stent restenosis
Interventional
Parallel
Randomized
Individual
Open -no one is blinded
Active
YES
YES
Institution is not considered as adjustment factor.
NO
Numbered container method
2
Treatment
Medicine |
The patients with hypertension who received ARBs except for azilsartan and olmesartan are enrolled. The patients are randomly divided into two groups (azilsartan and olmesartan groups) and treated for 12 weeks.
If the patient have percutaneous coronary intervention, we assess depressor effect and rate of in-stent restenosis at follow-up CAG.
20 | years-old | <= |
Not applicable |
Male and Female
1.Patients with hypertension who receive ARBs expect for azilsartan and olmesartan
2.Age is 20 years old or more.
3.Patients who undergo CAG
4.Patients who give their informed consent to participate for the present study.
1.Severe liver dysfunction.
2.Severe renal dysfunction.
3.Pregnancy or lactation in women.
4.Patients with a history of allergy to any component of the study medications.
5.Patients corresponding to the contraindication of study medications.
6.Ineligible patients according to the judgment by physician.
40
1st name | |
Middle name | |
Last name | Keijiro Saku |
Fukuoka University School of Medicine
Department of Cardiology
7-45-1 Nanakuma, Jonan-Ku, Fukuoka.
81-92-801-1011
saku-k@fukuoka-u.ac.jp
1st name | |
Middle name | |
Last name | Shin-ichiro Miura |
Fukuoka University School of Medicine
Department of Cardiology
7-45-1 Nanakuma, Jonan-Ku, Fukuoka.
81-92-801-1011
miuras@cis.fukuoka-u.ac.jp
Department of Cardiology, Fukuoka University School of Medicine
Department of Cardiology, Fukuoka University School of Medicine
Self funding
Japan
NO
福岡大学病院(Fukuoka University Hospital)
2015 | Year | 01 | Month | 17 | Day |
Unpublished
Completed
2012 | Year | 12 | Month | 21 | Day |
2013 | Year | 01 | Month | 01 | Day |
2015 | Year | 12 | Month | 31 | Day |
2016 | Year | 03 | Month | 30 | Day |
2016 | Year | 04 | Month | 30 | Day |
2016 | Year | 05 | Month | 31 | Day |
2015 | Year | 01 | Month | 17 | Day |
2016 | Year | 08 | Month | 14 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000018854
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |